RT Journal Article
T1 A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients.
A1 Garcia, J L
A1 Lozano, R
A1 Misiewicz-Krzeminska, I
A1 Fernandez-Mateos, J
A1 Krzeminski, P
A1 Alfonso, S
A1 Marcos, R A
A1 Garcia, R
A1 Gomez-Veiga, F
A1 Virseda, A
A1 Herrero, M
A1 Olmos, D
A1 Cruz-Hernandez, J J
K1 AR-V7
K1 Androgen receptor
K1 CD133
K1 Capillary nano-immunoassay
K1 Circulating tumor cells
K1 PTEN
AB Androgen receptor (AR) splice variant 7 (AR-V7) has been related with both a higher risk of prostate cancer (PC) progression and differential responsiveness to hormonal agents versus chemotherapy. The objective of this study was to investigate the feasibility of a novel capillary nano-immunoassay in assessing AR-V7 in plasma from PC patients. Patients with either localized or advanced PC were included in the study. Assessment of AR-V7 in plasma was performed through a capillary nano-immunoassay platform. Correlation with clinical data, stem cell biomarkers (such as CD133+), AR amplification and PTEN status was identified. The study included 72 PC patients. AR-V7 signal was detected in 21 (29%) patients: 17 (81%) had a Gleason score ≥7, 15 (71%) castration-resistant prostate cancer (CRPC), 18 (86%) metastatic disease and PSA (median) high than AR-V7 negative (p  Assessing the presence of AR-V7 in plasma from PC patients is feasible by a novel capillary nano-immunoassay. AR-V7 was observed in 29% of the tumors and is more frequent in aggressive tumors.
PB Springer
YR 2017
FD 2017-06-09
LK http://hdl.handle.net/10668/11290
UL http://hdl.handle.net/10668/11290
LA en
NO García JL, Lozano R, Misiewicz-Krzeminska I, Fernández-Mateos J, Krzeminski P, Alfonso S, et al. A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients. Clin Transl Oncol. 2017 Nov;19(11):1350-1357
NO Partiality supported by Grant from Gerencia Regional de Salud, Junta de Castilla y León (Refs: GRS 992/A/14 y BIO/SA35/14) and INNOCAMPUS Program (CEI10-1-0010)
DS RISalud
RD Apr 6, 2025